Symbio Holdings Limited Logo

Symbio Holdings Limited

SYM.AX

(2.0)
Stock Price

2,63 AUD

1.89% ROA

1.09% ROE

127.65x PER

Market Cap.

226.477.716,00 AUD

9.22% DER

13.31% Yield

0.84% NPM

Symbio Holdings Limited Stock Analysis

Symbio Holdings Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Symbio Holdings Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (9%), which means it has a small amount of debt compared to the ownership it holds

2 Dividend

Shareholders can rely on the company's remarkable dividend history, consistently paying dividends for the past five years, demonstrating a steadfast dedication to rewarding investors.

3 ROE

ROE in an average range (3.7%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 ROA

The stock's ROA (4.3%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 PBV

The stock's PBV ratio (1.53x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

6 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (82) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

10 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

11 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

Symbio Holdings Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Symbio Holdings Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Buy
4 Stoch RSI Sell

Symbio Holdings Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Symbio Holdings Limited Revenue
Year Revenue Growth
2005 1.603.436
2006 3.287.101 51.22%
2007 6.828.238 51.86%
2008 9.822.380 30.48%
2009 12.104.333 18.85%
2010 13.617.609 11.11%
2011 38.292.098 64.44%
2012 46.209.000 17.13%
2013 59.306.000 22.08%
2014 85.675.000 30.78%
2015 161.217.000 46.86%
2016 191.752.000 15.92%
2017 220.728.000 13.13%
2018 215.587.000 -2.38%
2019 214.890.000 -0.32%
2020 200.910.000 -6.96%
2021 202.599.000 0.83%
2022 431.520.000 53.05%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Symbio Holdings Limited Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 492.000 100%
2013 578.000 14.88%
2014 969.000 40.35%
2015 2.248.000 56.9%
2016 2.608.000 13.8%
2017 2.430.000 -7.33%
2018 4.168.000 41.7%
2019 6.867.000 39.3%
2020 8.754.000 21.56%
2021 10.648.000 17.79%
2022 28.180.000 62.21%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Symbio Holdings Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 1.119.592
2006 2.947.223 62.01%
2007 2.516.170 -17.13%
2008 2.985.516 15.72%
2009 3.326.095 10.24%
2010 3.647.925 8.82%
2011 6.400.232 43%
2012 492.000 -1200.86%
2013 12.973.000 96.21%
2014 15.915.000 18.49%
2015 24.790.000 35.8%
2016 29.048.000 14.66%
2017 37.203.000 21.92%
2018 43.182.000 13.85%
2019 47.260.000 8.63%
2020 43.668.000 -8.23%
2021 51.985.000 16%
2022 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Symbio Holdings Limited EBITDA
Year EBITDA Growth
2005 -1.391.133
2006 -3.189.873 56.39%
2007 -1.867.602 -70.8%
2008 246.671 857.12%
2009 1.082.034 77.2%
2010 1.103.206 1.92%
2011 4.461.381 75.27%
2012 6.097.000 26.83%
2013 8.936.000 31.77%
2014 11.658.000 23.35%
2015 16.370.999 28.79%
2016 21.164.000 22.65%
2017 22.057.000 4.05%
2018 21.192.000 -4.08%
2019 30.734.000 31.05%
2020 36.578.000 15.98%
2021 29.706.000 -23.13%
2022 53.220.000 44.18%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Symbio Holdings Limited Gross Profit
Year Gross Profit Growth
2005 142.958
2006 759.122 81.17%
2007 2.031.321 62.63%
2008 4.131.181 50.83%
2009 5.220.613 20.87%
2010 5.732.751 8.93%
2011 12.782.638 55.15%
2012 17.620.000 27.45%
2013 24.259.000 27.37%
2014 31.784.000 23.68%
2015 48.641.000 34.66%
2016 58.613.000 17.01%
2017 69.045.000 15.11%
2018 82.467.000 16.28%
2019 30.590.000 -169.59%
2020 33.009.000 7.33%
2021 26.697.000 -23.64%
2022 57.588.000 53.64%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Symbio Holdings Limited Net Profit
Year Net Profit Growth
2005 -1.406.147
2006 -3.250.320 56.74%
2007 -1.941.179 -67.44%
2008 170.386 1239.28%
2009 1.973.565 91.37%
2010 1.005.197 -96.34%
2011 3.069.115 67.25%
2012 4.141.000 25.88%
2013 5.778.000 28.33%
2014 7.184.000 19.57%
2015 8.990.000 20.09%
2016 12.066.000 25.49%
2017 11.859.000 -1.75%
2018 11.399.000 -4.04%
2019 11.947.000 4.59%
2020 15.578.000 23.31%
2021 5.677.000 -174.41%
2022 6.756.000 15.97%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Symbio Holdings Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Symbio Holdings Limited Free Cashflow
Year Free Cashflow Growth
2005 -209.740
2006 -72.607 -188.87%
2007 -18.911 -283.94%
2008 -1.950 -869.79%
2009 0 0%
2010 0 0%
2011 -314.189 100%
2012 4.742.000 106.63%
2013 7.709.000 38.49%
2014 5.735.000 -34.42%
2015 45.866.000 87.5%
2016 3.731.000 -1129.32%
2017 -24.397.000 115.29%
2018 -1.813.000 -1245.67%
2019 13.197.000 113.74%
2020 21.111.000 37.49%
2021 8.149.000 -159.06%
2022 6.114.000 -33.28%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Symbio Holdings Limited Operating Cashflow
Year Operating Cashflow Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 6.041.000 100%
2013 8.607.000 29.81%
2014 9.546.000 9.84%
2015 51.824.000 81.58%
2016 13.377.000 -287.41%
2017 -16.296.000 182.09%
2018 5.521.000 395.16%
2019 28.862.000 80.87%
2020 34.969.000 17.46%
2021 25.027.000 -39.73%
2022 17.161.000 -45.84%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Symbio Holdings Limited Capital Expenditure
Year Capital Expenditure Growth
2005 209.740
2006 72.607 -188.87%
2007 18.911 -283.94%
2008 1.950 -869.79%
2009 0 0%
2010 0 0%
2011 314.189 100%
2012 1.299.000 75.81%
2013 898.000 -44.65%
2014 3.811.000 76.44%
2015 5.958.000 36.04%
2016 9.646.000 38.23%
2017 8.101.000 -19.07%
2018 7.334.000 -10.46%
2019 15.665.000 53.18%
2020 13.858.000 -13.04%
2021 16.878.000 17.89%
2022 11.047.000 -52.78%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Symbio Holdings Limited Equity
Year Equity Growth
2005 1.373.130
2006 -288.662 575.69%
2007 -1.736.213 83.37%
2008 -1.565.827 -10.88%
2009 13.572 11637.19%
2010 386.523 96.49%
2011 2.554.761 84.87%
2012 10.777.000 76.29%
2013 14.240.000 24.32%
2014 19.048.000 25.24%
2015 38.968.000 51.12%
2016 68.347.000 42.99%
2017 76.233.000 10.34%
2018 81.983.000 7.01%
2019 138.953.000 41%
2020 150.052.000 7.4%
2021 162.039.000 7.4%
2022 164.345.000 1.4%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Symbio Holdings Limited Assets
Year Assets Growth
2005 2.365.777
2006 1.625.003 -45.59%
2007 1.485.044 -9.42%
2008 1.738.275 14.57%
2009 3.266.978 46.79%
2010 3.876.933 15.73%
2011 16.668.096 76.74%
2012 25.437.000 34.47%
2013 27.457.000 7.36%
2014 78.553.000 65.05%
2015 126.004.000 37.66%
2016 150.466.000 16.26%
2017 125.908.000 -19.5%
2018 182.700.000 31.08%
2019 234.803.000 22.19%
2020 209.639.000 -12%
2021 220.551.000 4.95%
2022 227.946.000 3.24%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Symbio Holdings Limited Liabilities
Year Liabilities Growth
2005 992.647
2006 1.913.665 48.13%
2007 3.221.257 40.59%
2008 3.304.102 2.51%
2009 3.253.406 -1.56%
2010 3.490.410 6.79%
2011 14.113.335 75.27%
2012 14.660.000 3.73%
2013 13.217.000 -10.92%
2014 59.505.000 77.79%
2015 87.036.000 31.63%
2016 82.119.000 -5.99%
2017 49.675.000 -65.31%
2018 100.717.000 50.68%
2019 95.850.000 -5.08%
2020 59.587.000 -60.86%
2021 58.512.000 -1.84%
2022 63.601.000 8%

Symbio Holdings Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.46
Net Income per Share
0.02
Price to Earning Ratio
127.65x
Price To Sales Ratio
1.07x
POCF Ratio
8.06
PFCF Ratio
34.63
Price to Book Ratio
1.37
EV to Sales
0.98
EV Over EBITDA
8.85
EV to Operating CashFlow
7.35
EV to FreeCashFlow
31.47
Earnings Yield
0.01
FreeCashFlow Yield
0.03
Market Cap
0,23 Bil.
Enterprise Value
0,21 Bil.
Graham Number
0.94
Graham NetNet
0.09

Income Statement Metrics

Net Income per Share
0.02
Income Quality
15.84
ROE
0.01
Return On Assets
0.01
Return On Capital Employed
0.02
Net Income per EBT
1.1
EBT Per Ebit
0.36
Ebit per Revenue
0.02
Effective Tax Rate
-0.1

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.06
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.12
Operating Profit Margin
0.02
Pretax Profit Margin
0.01
Net Profit Margin
0.01

Dividends

Dividend Yield
0.13
Dividend Yield %
13.31
Payout Ratio
3.06
Dividend Per Share
0.35

Operating Metrics

Operating Cashflow per Share
0.33
Free CashFlow per Share
0.08
Capex to Operating CashFlow
-0.77
Capex to Revenue
-0.1
Capex to Depreciation
-1.14
Return on Invested Capital
0.03
Return on Tangible Assets
0.02
Days Sales Outstanding
80.79
Days Payables Outstanding
59
Days of Inventory on Hand
2.32
Receivables Turnover
4.52
Payables Turnover
6.19
Inventory Turnover
157.12
Capex per Share
-0.25

Balance Sheet

Cash per Share
0,42
Book Value per Share
1,92
Tangible Book Value per Share
0.35
Shareholders Equity per Share
1.92
Interest Debt per Share
0.19
Debt to Equity
0.09
Debt to Assets
0.07
Net Debt to EBITDA
-0.89
Current Ratio
1.95
Tangible Asset Value
0,03 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
0.09
Working Capital
0,04 Bil.
Intangibles to Total Assets
0.59
Average Receivables
0,05 Bil.
Average Payables
0,03 Bil.
Average Inventory
1196500
Debt to Market Cap
0.07

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Symbio Holdings Limited Dividends
Year Dividends Growth
2010 0
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Symbio Holdings Limited Profile

About Symbio Holdings Limited

Symbio Holdings Limited provides communication services to software companies, telecom providers, and enterprise customers in Australia and Internationally. The company operates through three divisions: Communications Platform as a Service, Unified Communications as a Service, and Telecom as a Service. It offers IP enabling communication services; automated systems for number porting and service configuration; and cloud communication services. In addition, it provides call termination, global voice, messaging, and RSP and reseller services. The company was formerly known as MNF Group Limited and changed its name to Symbio Holdings Limited in November 2021. Symbio Holdings Limited was founded in 2002 and is headquartered in Sydney, Australia.

CEO
Mr. Rene Sugo B.Eng. (Hon)
Employee
530
Address
580 George Street
Sydney, 2000

Symbio Holdings Limited Executives & BODs

Symbio Holdings Limited Executives & BODs
# Name Age
1 Mr. Iain Falshaw
Chief Executive Officer – Enterprise
70
2 Mr. John Boesen
Chief Technology Officer
70
3 Mr. Nick Elvin
Company Secretary
70
4 Ms. Kate Denton
Group Financial Controller & Chief Financial Officer
70
5 Mr. Dylan Brown
Chief Executive Officer of Connect
70
6 Ms. Helen Fraser
Chief Legal Officer
70
7 Ms. Cathy Doyle
Chief Experience Officer
70
8 Mr. Rene Sugo B.Eng. (Hon)
Co-Founder, Group Chief Executive Officer & Executive Director
70
9 Mr. Andy Fung B.E. MCom
Co- Founder & Non Executive Director
70
10 Mr. Jon Cleaver
Chief Executive Officer - TaaS
70

Symbio Holdings Limited Competitors